HEMOBLAST Bellows
Dilon Technologies, Inc. · Decision date Dec 15, 2017
What did the FDA approve?
The FDA database entry records approval of HEMOBLAST Bellows under PMA number P170012, with a decision date of December 15, 2017. The applicant is Dilon Technologies, Inc., and the device is classified as an absorbable collagen hemostatic agent with thrombin under product code PMX.
The stated indication is use in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical. The statement explicitly excludes neurosurgical, ophthalmic, and urological procedures. The source does not provide supplement type, supplement reason, or clinical data supporting the approval.
FDA approval order statement
Approval of the Hemoblast Bellows. This device is indicated for surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 15, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170012
- Regulatory pathway
- Premarket approval application
- Applicant
- Dilon Technologies, Inc.
- Product code
- PMX
- Decision code
- APPR
- Decision date
- Dec 15, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Absorbable collagen hemostatic agent with thrombin.
- Applicant
- Dilon Technologies, Inc.
- Product code
- PMX
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170012 received
Application receipt date recorded by FDA.
P170012 · FDA decision
APPR
P170012/S032 · Related supplement
HEMOBLAST Bellows
Timeline entries are records held by MedtechLedger for P170012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HEMOBLAST BellowsP170012/S032 | Dilon Technologies, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Dilon Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 12050 Jefferson Ave., Suite 340, Newport News, VA, 23606
Sources and methodology
- Original FDA record: P170012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records